Varespladib (sodium)

Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively[1].

Product Specifications

CAS Number

[172733-42-5]

Product Name Alternative

LY315920 (sodium)

UNSPSC

12352005

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/varespladib-sodium.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCC1=C(C(C(N)=O)=O)C2=C(OCC(O[Na])=O)C=CC=C2N1CC3=CC=CC=C3

Molecular Formula

C21H19N2NaO5

Molecular Weight

402.38

References & Citations

[1]Snyder DW, et al. Pharmacology of LY315920/S-5920, [[3- (aminooxoacetyl) -2-ethyl-1- (phenylmethyl) -1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther. 1999 Mar;288 (3) :1117-24.|[2]Hori Y, et al. Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46 (11) :4050-61.